Costantino Luca, Barlocco Daniela
University of Modena & Reggio Emilia, Dipartimento di Scienze della Vita, Via Campi 183, 41100 Modena, Italy.
Future Med Chem. 2015;7(3):315-36. doi: 10.4155/fmc.14.167.
After many years of research, obesity is still a disease with an unmet medical need. Very few compounds have been approved, acting mainly on neuromediators; researches, in recent years, pointed toward compounds potentially safer than first-generation antiobesity drugs, able to interact with one or more (multitarget therapy) receptors for substances produced by the gut, adipose tissue and other targets outside CNS. Other holistic approaches, such as those involving gut microbiota and plant extracts, appeared recently in the literature, and undoubtedly will contribute to the discovery of a valuable therapy for this disease. This review deals with the positive results and the pitfalls obtained following these approaches, with a view on their clinical trial studies.
经过多年研究，肥胖仍然是一种医疗需求未得到满足的疾病。获批的化合物极少，主要作用于神经介质；近年来的研究指向了可能比第一代抗肥胖药物更安全的化合物，这些化合物能够与肠道、脂肪组织及中枢神经系统以外其他靶点产生的物质的一种或多种（多靶点疗法）受体相互作用。其他整体方法，如涉及肠道微生物群和植物提取物的方法，最近出现在文献中，无疑将有助于发现针对这种疾病的有效疗法。本综述探讨了这些方法所取得的积极成果和存在的问题，并着眼于它们的临床试验研究。
